Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.70 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 3/20 | 0.39 |
| ▸ | CDC25A | P30304 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401471 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL31238461 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL3491665 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL3491660 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL13401488 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL267551 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL31237650 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL20738425 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL21331728 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2PTPN1BCHEACHE | |
| SCHEMBL21900813 | 0.85 | HSD11B1 (0.74) | HSD11B1HSD11B2PTPN1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-7893299-B2 | Acanthoic amide derivatives; inflammation, cancer, cachexia, cardiovascular disease, infections, diabetes, otitis media, sinusitis, transplant rejection | NEREUS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | HSD11B1 720/4885HSD11B2 1528/4885PTPN1 2008/4885 |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | HSD11B1 720/4885HSD11B2 1528/4885PTPN1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.